TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03464058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 immediate release capsules
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 immediate release capsules
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 immediate release capsules
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 immediate release capsules
Description: Oral capsules
Study: NCT02467335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-663068
Description: BMS-663068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-663068
Description: BMS-663068
Study: NCT01733849

Intervention type: OTHER
Intervention: Stool sample
Description: Samples will be tested to determine the presence or absence of rotavirus.

Intervention type: OTHER
Intervention: Stool sample
Description: Samples will be tested to determine the presence or absence of rotavirus.

Intervention type: OTHER
Intervention: Data collection
Description: Log books

Intervention type: OTHER
Intervention: Data collection
Description: Log books
Study: NCT01539317

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical liquid lidocaine
Description: active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical liquid lidocaine
Description: active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical saline
Description: saline applied to the vestibule mucosa will not reverse the local tenderness

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical saline
Description: saline applied to the vestibule mucosa will not reverse the local tenderness
Study: NCT04461249

Intervention type: DRUG
Intervention: Latanoprost 0.005% Ophthalmic Solution
Description: Latanoprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.

Intervention type: DRUG
Intervention: Travoprost 0.004% ophthalmic solution
Description: Travoprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.

Intervention type: DRUG
Intervention: Tafluprost Ophthalmic 0.0015% Ophthalmic Solution
Description: Tafluprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.
Study: NCT04322214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat 150 MG
Description: once daily cobicistat (150 mg QD) for 5 days
Study: NCT03066518

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melatonin 5 mg
Study: NCT03434691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microdialysis Probe (Muscle microdialysis)
Description: Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were determined at baseline and then every six hours for the following 72 hours after randomization.~During the study period, conventional treatment was continued as per usual practice. Fluid challenges were performed, and repeated as necessary, to maintain central venous pressure (CVP) ≥8 and pulmonary arterial occlusion pressure (PAOP) ≥12 mmHg. Norepinephrine was titrated to maintain mean arterial pressure (MAP) ≥65 mmHg. Packed red blood cells were transfused when Hemoglobin (Hb) concentrations decreased below 7 g/dL, or if the patient exhibited clinical signs of inadequate systemic oxygen supply.
Study: NCT04322214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: once daily lactose capsules (as aspect cobicistat capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: once daily lactose capsules (as aspect cobicistat capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GHB
Description: single oral dose of GHB (25 mg/kg) on days 5 and 17
Study: NCT03066518

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01333826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zomba Cash Transfer Program
Description: Cash transfers were provided monthly to a randomly selected sample of school aged girls. Amounts were also varied in both treatment arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zomba Cash Transfer Program
Description: Cash transfers were provided monthly to a randomly selected sample of school aged girls. Amounts were also varied in both treatment arms.
Study: NCT03434691

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microdialysis Probe (Muscle microdialysis)
Description: Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were determined at baseline and then every six hours for the following 72 hours after randomization.~During the study period, conventional treatment was continued as per usual practice. Fluid challenges were performed, and repeated as necessary, to maintain central venous pressure (CVP) ≥8 and pulmonary arterial occlusion pressure (PAOP) ≥12 mmHg. Norepinephrine was titrated to maintain mean arterial pressure (MAP) ≥65 mmHg. Packed red blood cells were transfused when Hemoglobin (Hb) concentrations decreased below 7 g/dL, or if the patient exhibited clinical signs of inadequate systemic oxygen supply.
Study: NCT00115180

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00839202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FVIII immuno-assay
Description: There is no intervention. This is a study of the differences in assays.
Study: NCT03294265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support sessions
Description: Stages of mourning and motivation Patients introduce themselves, share their experience and mention a strategy on moving on to the next stage Reminder of metabolic control goals Leaders write on the board metabolic variables and ask everybody the goal values. Patients share their results and mention plans to improve them Self-care activities Leaders ask who owns a glucometer, how regularly they use it, its importance and consequences of not doing so.~Simplified meal plan Everyone brings a snack. Leaders ask if each snack is appropriate, how everyone carries out their meal plan, barriers and possible strategies Activities to increase physical activity Everyone compares who achieves 10 thousand steps/day and who doesn't, then mention benefits of exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reminders
Description: Creation of a group on WhatsApp to send leaders and patients a weekly reminder on the different areas of self-care, such as foot care, self-monitoring, adherence to meal plan, medication and exercise.~This intervention will be applied to both groups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminders
Description: Creation of a group on WhatsApp to send leaders and patients a weekly reminder on the different areas of self-care, such as foot care, self-monitoring, adherence to meal plan, medication and exercise.~This intervention will be applied to both groups.
Study: NCT01691989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: 150 mcg orally once a day for 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: oral doses once a day for 26 weeks
Study: NCT01409174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Phase I Starting dose: 1 mg/kg by vein over 90 minutes on Day 1 of each 3 week cycle for Induction 12 weeks, then Day 1 of Cycle 1 for Consolidation 12 weeks and Day 1 of each 12 week cycle in Maintenance.~Phase II dose: Maximum tolerated dose (MTD) from Phase I.
Study: NCT03434691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanyl
Description: Only the dose of remifentanyl (initial infusion of 6 µg/kg/h) can be changed to achieve a Goal of sedation: Richmond agitation-sedation scale 0 to -2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanyl
Description: Only the dose of remifentanyl (initial infusion of 6 µg/kg/h) can be changed to achieve a Goal of sedation: Richmond agitation-sedation scale 0 to -2.
Study: NCT06183320

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restoration with Incremental Composite in Proximal Wall
Description: Proximo-occlusal lesions will receive the self-etch adhesive system Ambar Universal APS with selective acid etching, according to the manufacturers instrucions. Then, proximal wall will be completely restored with Vittra APS composite resin, using the triangular incremental traditional technique described for classe II restorations. Then, Opus Bulk Fill Flow APS will be used in the bulk technique with up to 5mm depth increments, leaving 1 mm in the occlusal for incremental Vittra APS composite resin, that will be used with the traditional incremental technique. Both composites will be light-cured with VALO light-cure unit (Ultradent, USA) for 40 seconds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restoration with Bulk Fill Composite in Proximal Wall
Description: Proximo-occlusal lesions will receive the self-etch adhesive system Ambar Universal APS with selective acid etching, according to the manufacturers instrucions. Then, Opus Bulk Fill Flow APS resin will be used in the bulk technique with up to 5mm depth increments, leaving 1 mm in the occlusal for incremental Vittra APS composite resin, that will be used with the traditional incremental technique. Both composites will be light-cured with VALO light-cure unit (Ultradent, USA) for 40 seconds.
Study: NCT00003906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene
Description: 60 mg/day plus placebo for 5 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20 mg/day plus placebo for 5 years
Study: NCT01675973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RANEXA
Description: 500mg BID up to 1000mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RANEXA
Description: 500mg BID up to 1000mg BID
Study: NCT01409174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 200 mg/m\^2 by mouth 1 time a day on Days 2-5 of each Induction cycle (four 3 week cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m\^2 by vein over 1 hour on Days 2-4 of each Induction cycle (four 3 week cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2b
Description: 5 million U/m2 subcutaneously on Days 2-6 of each 3 week Induction cycle (four 3 week cycles) and each 4 week Consolidation cycle (three 4 week cycles).
Study: NCT02439515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cycling
Description: Voluntary cycling augmented by electrical stimulation and biofeedback

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balance
Description: Balance control exercises with visual biofeedback

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard physical therapy
Description: It consists of stretching, muscular conditioning, exercises for trunk control, standing, and walking training, and upper limb rehabilitation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy
Description: It consists of stretching, muscular conditioning, exercises for trunk control, standing, and walking training, and upper limb rehabilitation.
Study: NCT02188628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H-Man
Description: H-man is a portable end-effector planar upper limb robot.
Study: NCT04317742

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Healthy Using the Internet (SHUTi) Intervention Group
Description: SHUTi is a fully automated, interactive and tailored web-based program that incorporates the primary tenets of face-to-face CBT-I, including sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. Intervention content is presented in six Cores, metered out over time.
Study: NCT02188628

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Additional Conventional Therapy
Description: Repetitive goals based arm therapy
Study: NCT02818296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active IU CBM-I

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control CBM-I
Study: NCT04823936

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: core stability training
Description: core stability training program for 30 minutes including Supine abdominal draw in Abdominal draw in with double knee to chest Trunk twist while sitting on medical ball Lying supine on the medical ball and rotating the trunk to the sides Contracting abdominal muscles while lying in a supine position and pulling the limbs upward with arms and legs kept close Bringing up the arms and legs simultaneously in the prone position Bridging with head on medical ball hold this position for 3-5 s then slowly relaxes Bridging while shoulders and hands are on the floor and one leg is raised Lying supine on the medical ball and holding the abdomen in and bringing with one leg up
Study: NCT04317742

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Online Patient Education (PE) Control Group
Description: The online PE program provides static information about: insomnia symptoms; the impact, prevalence, and causes of insomnia; when to see a doctor; and basic lifestyle, environmental, and behavioral strategies to improve sleep.
Study: NCT02102802

Intervention type: DRUG
Intervention: Midomafetamine
Description: 125, 75, or 30 mg midomafetamine HCl followed 1.5 to 2 hours later by a supplemental dose of midomafetamine HCl half the initial dose

Intervention type: BEHAVIORAL
Intervention: Therapy
Description: Manualized therapy
Study: NCT01409174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: 9 million IU/m\^2 by vein as a continuous infusion on Days 2-5 of each 3 week Induction cycle (four 3 week cycles) and each 4 week Consolidation cycle (three 4 week cycles).
Study: NCT03302429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRF/ BCP
Description: Platelet rich fibrin combined with biphasic calcium phosphate(experimental group)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone graft
Description: Bone obtained from the same individual who receiving the graft
Study: NCT03640624

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment
Description: 1. Assessment by gynaecologist and dermatologist, resulting in tailored vulvar care, including daily topical lidocaine 5% ointment. Other topical or oral medication, such as oestradiol cream or oral antidepressants will be prescribed on individual basis.~2. Tailored physiotherapy targeting muscular dysfunction, utilizing: Patient education, pelvic floor muscle exercises (contraction and relaxation), EMG-biofeedback. Low frequent electrical stimulation, massage, stretching and myofascial release and trigger point treatment of the pelvic floor. Desensitization exercises (manually or vaginal dilator). Relaxation and body awareness. Minimum one visit per month.~3. Guided imagery sessions, minimum twice a week using a sound track that is developed for vulvodynia patients.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual in accordance with local guidelines by specialist in gynaecology, including a minimum of two visits (when diagnosis is made and after 3 - 6 months)
Study: NCT00298155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: goserelin with dutasteride
Description: Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd; continue bicalutamide for one more week.
Study: NCT04474587

Intervention type: OTHER
Intervention: Indirect calorimetry
Description: Measurements of REE by indirect calorimetry
Study: NCT00298155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: goserelin with bicalutamide and dutasteride
Description: Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: goserelin with bicalutamide and dutasteride and ketoconazole
Description: Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot), begin dutasteride 3.5 mg qd and ketoconazole 200 mg tid (with hydrocortisone 30 mg).
Study: NCT02763098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remi 0.1
Description: Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.1 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
Study: NCT01907646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bladder training
Description: vescical catheter

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No bladder training
Study: NCT04322214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GHB
Description: single oral dose of GHB (25 mg/kg) on days 5 and 17
Study: NCT03119662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visipaque
Description: 100 mL iodixanol (Visipaque Injection 320 mg I/mL), followed by a 10 mL saline flush to ensure delivery of the full dose of Visipaque.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 100 mL saline, followed by a 10 mL saline flush.
Study: NCT04493879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bioptron Light Therapy (BLT)
Description: BLT for 30 days 10 minutes every day. The treatment points displayed were: one point in the right jugal mucosa, one point in the left jugal mucosa, one point in the lower lip 's inner mucosa, analgesics, anti-inflammatory treatment, and antimicrobial treatment for any new mouth infections)
Study: NCT01156441

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical mitral valve repair w/ mitral valve annuloplasty
Description: Mitral valve repair will be performed via median sternotomy, utilizing cardiopulmonary bypass and moderate hypothermia. The mitral valve will be approached through a left atrial incision. Following inspection of the valve, mitral valve annuloplasty will be accomplished with a complete semi-rigid annuloplasty ring. Additional techniques to address residual regurgitation will be at the discretion of the surgeon. The left atriotomy will then be closed and the patient weaned off and separated from the cardiopulmonary bypass.~Intraoperative transesophageal echocardiography will be performed on all study volunteers.
Study: NCT02763098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remi 0.2
Description: .Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.2 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remi 0.3
Description: Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.3 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
Study: NCT00767715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: physician determined dose, oral, daily, 5 months
Study: NCT00586937

Intervention type: BEHAVIORAL
Intervention: questionnaires or telephone interview
Description: In the first phase, a random sample of lung cancer survivors will complete a comprehensive telephone interview or questionnaire by self-report focusing on assessment of quality of life and related covariates. We estimate the total time for completion of the survey by telephone interview or self-report to be 45-60 minutes. second phase of the study, a subset of telephone survey participants will take part in a focus group discussion that will explore their perceptions of barriers for delivery of post-treatment medical and psychosocial follow-up care.
Study: NCT01885338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive placebo capsule
Study: NCT03767387

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trimodal Prehabilitation
Description: Prehabilitation before major surgery consisting of: i) motivational interview to assess patient's adherence profile and to co-design the characteristics of the physical activity program with the patient; ii) personalised program to promote daily physical activity; and iii) supervised high-intensity endurance exercise training program.